Replicant / stav for disease treatment and methods of use

A composition comprising:

• a) a vector comprising a Replicant comprising at least a first mRNA (messenger RiboNucleic Acid) encoding an antigen, where the vector is adapted to express the antigen;
• b) a first DNA molecule comprising a first sequence and a first length, where the first sequence is selected from the group consisting of SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, and SEQ ID NO:45;
• and
• c) a second DNA molecule comprising a second sequence and a second length, where the second length exceeds the first length by not more than between:
• a lower limit of approximately one base, and
• an upper limit of approximately fifty bases, where the Percent Complimentary of the second sequence is at least eighty (80) percent with respect to the first sequence, where the first DNA molecule and the second DNA molecule are annealed to form a STAV (a dsDNA (double-stranded DeoxyriboNucleic Acid) molecule).

A method for treating a human subject suffering from a malady selected from the group consisting of an immune-related disorder, a cancer, an autoimmunity disease, and an infection comprising:

• determining whether the human subject is suffering from the malady comprising:
• i) isolating a sample from the human subject;
• ii) performing an assay to determine the human subject is suffering from the malady, then administering a composition comprising:
• a) a first DNA molecule comprising a first sequence and a first length;
• b) a second DNA molecule comprising a second sequence and a second length, where the first DNA molecule and the second DNA molecule are annealed to form a STAV (a dsDNA (double stranded DeoxyriboNucleic Acid) molecule);
• and
• c) a vector comprising a Replicant, the Replicant comprising at least a first mRNA (messenger RiboNucleic Acid) encoding an OVA antigen (SEQ ID NO:48), where the vector is adapted to express the OVA antigen, where administering the composition to the human subject modulates one or both innate and adaptive immunity to treat the malady.